HLN

Haleon plc is a global consumer health company that develops, manufactures, and markets over-the-counter medications, oral health products, and vitamins, minerals, and supplements. Headquartered in Weybridge, United Kingdom, the company was established in 2022 following its demerger from GSK plc and began trading independently on the London Stock Exchange in July 2022. Haleon's portfolio includes leading brands such as Sensodyne and Paradontax in oral health, Advil and Panadol in pain relief, Centrum and Emergen-C in vitamins and supplements, and Theraflu in respiratory health. The company employs approximately 22,000 people globally and operates manufacturing facilities across multiple continents, serving consumers in over 100 countries. Haleon ranks as one of the world's largest consumer health companies by revenue, generating approximately £11 billion in annual sales. The business operates through five regional segments: North America, Europe, Latin America, Middle East & Africa, and Asia Pacific. Since its spinoff, Haleon has focused on streamlining operations, investing in its power brands, and pursuing strategic acquisitions to strengthen its market position. The company combines heritage brands with scientific expertise to address everyday health needs across pain relief, respiratory health, digestive wellness, and oral care categories.